Theerachai Thammathiwat

Dr. Theerachai Thammathiwat

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
TTTheerachai Thammathiwat
Theerachai Thammathiwat
STSomkanya Tungsanga
Somkanya Tungsanga
KTKanitha Tiankanon
Kanitha Tiankanon
PTPattama Torvorapanit
Pattama Torvorapanit
WCWorawat Chumpangern
Worawat Chumpangern
NTNatavudh Townamchai
Natavudh Townamchai

1 May 2020 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
TTTheerachai Thammathiwat
Theerachai Thammathiwat
KTKhajohn Tiranathanagul
Khajohn Tiranathanagul
MLManeerut Limjariyakul
Maneerut Limjariyakul
PCPajaree Chariyavilaskul
Pajaree Chariyavilaskul
KTKullaya Takkavatakarn
Kullaya Takkavatakarn
SESomchai Eiam‐Ong
Somchai Eiam‐Ong

15 May 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
TTTheerachai Thammathiwat
Theerachai Thammathiwat
ABAthiphat Banjongjit
Athiphat Banjongjit
KIKroonpong Iampenkhae
Kroonpong Iampenkhae
NTNatavudh Townamchai
Natavudh Townamchai
TKTALERNGSAK KANJANABUCH
TALERNGSAK KANJANABUCH
Vaccines against SARS-CoV-2 (COVID-19) proved beneficial for COVID-19 disease attenuation and preventing virus spreading. Cumulative reports of the rarity of antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV) raise concerns about its relationship with COVID-19 vaccination. Several case reports described ANCA-associated pauci-immune glomerulonephritis (ANCA-GN) following COVID-19 vaccination with some uniqueness. We systematically reviewed COVID-19 vaccine-induced ANCA-GN from PubMed, SCOPUS, and Cochrane library databases until 1 January 2023 according to PRISMA guidelines and presented our three cases. Twenty-six cases from 25 articles, including our 3 cases, were analyzed. Most cases were diagnosed following the second dose of the COVID-19 vaccine (59%) with a median (IQR) interval onset of 14 (16) days. The highest prevalence was related to the mRNA-type vaccine. Anti-myeloperoxidase (MPO) ANCA was far more common than the other ANCAs, with various positive autoantibodies. Fourteen cases (out of 29 cases, 48%) had extra-kidney AAV manifestation. Although severe kidney injury was observed in 10/29 (34%), remission was achieved in 89% (25/28) with no death. The mechanisms of the vaccine-inducing ANCA-GN were postulated here. Since ANCA-GN after the COVID-19 vaccine was rare, the benefit of the COVID-19 vaccine could outweigh the risk of ANCA-GN side effects in the pandemic era.

29 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
TTTheerachai Thammathiwat
Theerachai Thammathiwat
LCLaor Chompuk
Laor Chompuk
SWSuchin Worawichawong
Suchin Worawichawong
VBVijitr Boonpucknavig
Vijitr Boonpucknavig
SSSupinda Sirilak
Supinda Sirilak
TKTALERNGSAK KANJANABUCH
TALERNGSAK KANJANABUCH
Vaccination against the SARS-CoV-2 virus (COVID-19) has proven to be the most effective measure to prevent the spread and reduce infection severity. A case report of de novo membranous nephropathy (MN) following immunization with inactivated virus vaccine (CoronaVac®, Sinovac Biotech) is presented here. A 53-year-old man presented with a sudden onset of leg edema a week after receiving an inactivated virus vaccine and a relapse of nephrotic syndrome (NS) with acute kidney injury (AKI) after a booster dose. Screening for serum anti-phospholipase A2 receptor antibody and secondary causes of MN were negative. Kidney biopsy revealed an early MN pattern with focal spike formation, whilst numerous subepithelial electron-dense deposits and a few small deposits in the mesangial area were observed through electron microscopy. A short course of steroids and oral cyclophosphamide was prescribed, resulting in the complete remission of NS and AKI. MN following SARS-CoV-2 vaccination should call for medical importance. Awareness of the association between vaccination and MN should be kept in mind to avoid unnecessary treatment with long-term immunosuppressive agents.

3 August 2023 in Nephrology
Verified
Journal Article
Closed access
TKTALERNGSAK KANJANABUCH
TALERNGSAK KANJANABUCH
SISuramath Isaranuwatchai
Suramath Isaranuwatchai
TNTanawin Nopsopon
Tanawin Nopsopon
TTTheerachai Thammathiwat
Theerachai Thammathiwat
TPThitipong Pooprasert
Thitipong Pooprasert
TTThe Nephrology Society Of Thailand
The Nephrology Society Of Thailand

28 September 2023 in Medical Mycology Case Reports
Verified
Journal Article
Open access
TTTheerachai Thammathiwat
Theerachai Thammathiwat
STSajja Tatiyanupanwong
Sajja Tatiyanupanwong
UPUraiwan Parinyasiri
Uraiwan Parinyasiri
DWDhammika Leshan Wannigama
Dhammika Leshan Wannigama
TCTanittha Chatsuwan
Tanittha Chatsuwan
TKTALERNGSAK KANJANABUCH
TALERNGSAK KANJANABUCH
Two cases of PD-associated peritonitis due to Cunninghamella (C. bertholletiae and C. guizhouensis) were reported here with favorable outcomes, albeit presenting with septicemia. Both patients presented with classic features of bacterial peritonitis, cloudy effluent with a neutrophil predominance, followed by fever and septicemia/septic shock. The pathogen species were confirmed and verified by molecular phylogeny using universal and specific fungal primers. All isolations were susceptible/intermediately susceptible to amphotericin B but resistant to other antifungal agents, including triazoles, caspofungin, and terbinafine. Both cases were successfully treated with timely PD catheter removal and antifungal medications for 2–4 weeks.